Lapaquistat acetate - CAS 189060-13-7
Catalog number: B0084-061834
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Lapaquistat acetate, also referred as TAK475, is a squalene synthase inhibitor. As a cholesterol-lowering drug, Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-061834 5 mg $498 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
White to off-white crystalline solid
2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid; (1-(2-(1-(2-carboxyoxy-1,1-dimethylethyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydrobenzo(e)(1,4)oxazepin-3-yl)acetyl)piperidin-4-yl)acetic acid; 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid; lapaquistat; TAK 475; TAK-475; TAK475
A novel squalene synthase inhibitor
Canonical SMILES:
1.Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs.
Ebihara T1, Teshima K1, Kondo T1, Tagawa Y1, Moriwaki T1, Asahi S1. Drug Res (Stuttg). 2016 Feb 2. [Epub ahead of print]
The pharmacokinetics of TAK-475 (lapaquistat acetate), a squalene synthase inhibitor, was investigated in rats and dogs. After oral administration of 14C-labeled TAK-475 ([14C]TAK-475) to rats and dogs at a dose of 10 mg/kg, the bioavailability (BA) was relatively low at 3.5 and 8.2%, respectively. The main component of the radioactivity in the plasma was M-I, which has a comparable pharmacological activity to TAK-475 in vitro. The radioactivity in the portal plasma after intraduodenal administration of [14C]TAK-475 to portal vein-cannulated rat was also mainly M-I, suggesting that most of the TAK-475 was hydrolyzed to M-I during the permeable process in the intestine. The concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration of [14C]TAK-475 to rats. The main elimination route of the radioactivity was fecal excretion after oral administration of [14C]TAK-475 to rats and dogs, and the absorbed radioactivity was mainly excreted via the bile as M-I in rats.
2.Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
Davidson MH1. Curr Atheroscler Rep. 2009 Jan;11(1):67-70.
There remains an unmet need to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients who are maximized on current therapy or intolerant to statins. Several novel agents have been developed to lower LDL-C, either as monotherapy or in combination with statins. These novel therapies include squalene synthase inhibitors, microsomal triglyceride transfer protein inhibitors, and antisense apolipoprotein B. Although each of these novel therapies effectively lowers LDL-C, challenges remain in the clinical development to assess long-term safety.
3.Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans.
Ebihara T1, Takeuchi T1, Moriya Y1, Tagawa Y1, Kondo T1, Moriwaki T1, Asahi S1. Drug Res (Stuttg). 2016 Mar 24. [Epub ahead of print]
TAK-475 (lapaquistat acetate) is a squalene synthase inhibitor and M-I is a pharmacologically active metabolite of TAK-475. Preclinical pharmacokinetic studies have demonstrated that most of the dosed TAK-475 was hydrolyzed to M-I during the absorption process and the concentrations of M-I in the liver, the main organ of cholesterol biosynthesis, were much higher than those in the plasma after oral administration to rats. In the present study, the mechanism of the hepatic uptake of M-I was investigated.The uptake studies of 14C-labeled M-I into rat and human hepatocytes indicated that the uptakes of M-I were concentrative, temperature-dependent and saturable in both species with Km values of 4.7 and 2.8 μmol/L, respectively. M-I uptake was also inhibited by cyclosporin A, an inhibitor for hepatic uptake transporters including organic anion transporting polypeptide (OATP). In the human hepatocytes, M-I uptake was hardly inhibited by estrone 3-sulfate as an inhibitor for OATP1B1, and most of the M-I uptake was Na+-independent.
4.Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S1, Frishman WH. Cardiol Rev. 2009 Mar-Apr;17(2):70-6. doi: 10.1097/CRD.0b013e3181885905.
Hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular diseases. The most popular agents for cholesterol reduction are the statin drugs, which are competitive inhibitors of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the primary rate-limiting enzyme in the hepatic biosynthesis of cholesterol. Although relatively safe and effective, the available statins can cause elevations in liver enzymes and myopathy. Squalene synthase is another enzyme that is downstream to HMG-CoA reductase in the cholesterol synthesis pathway and modulates the first committed step of hepatic cholesterol biosynthesis at the final branch point of the cholesterol biosynthetic pathway. Squalene epoxidase and oxidosqualene cyclase are other enzymes that act distally to squalene synthase. Pharmacologic inhibitors of these downstream enzymes have been developed, which may reduce low-density lipoprotein cholesterol and reduce the myopathy side effect seen with upstream inhibition of HMG-CoA.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CP 81282
(CAS: 121584-61-0)

CP 81282 shows human renin and endothiapepsin inhibitory efficacy, but no detailed data has been published yet.

CAS 549-18-8 Amitriptyline Hydrochloride

Amitriptyline Hydrochloride
(CAS: 549-18-8)

Amitriptyline inhibits serotonin receptor, norepinephrine receptor, 5-HT4, 5-HT2 and sigma 1 receptor with IC50 of 3.45 nM, 13.3 nM, 7.31 nM, 235 nM and 287 nM,...

CAS 5502-96-5 NAADP tetrasodium salt

NAADP tetrasodium salt
(CAS: 5502-96-5)

NAADP tetrasodium salt is a Ca2+ mobilizing agent. It is an activator of intracellular Ca2+ release via IP3 and cyclic ADP ribose-independent mechanism.

CAS 1617-53-4 Amentoflavone

(CAS: 1617-53-4)

Amentoflavone, which comes from the seed of Ginkgo biloba L, can interact with many other medications by being a potent inhibitor of CYP3A4 and CYP2C9, which ar...

CAS 477-43-0 Dehydrocostus lactone

Dehydrocostus lactone
(CAS: 477-43-0)

Dehydrocostus lactone and CL from root of S. lappa have anti-colorectal cancer activities through inhibiting Wnt/β-catenin pathway.

CI 972
(CAS: 115787-68-3)

This active molecular is a potent purine nucleoside phosphorylase inhibitor and a T cell-selective immunosuppressive agent. CI-972 inhibited proliferation of hu...

CAS 1046045-61-7 FGH10019

(CAS: 1046045-61-7)

FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM, 5-10 times lower than the IC50 of fatostatin (~10 μM).

CAS 587-63-3 Dihydrokavain

(CAS: 587-63-3)

Dihydrokavain is a kavalactone source from kava beverages used in herbal medicine to treat sleep disturbances, as well as stress and anxiety.

(CAS: 1652591-81-5)

GSK-484, a benzoimidazole derivative, has been found to be an effective reversible PAD-4 inhibitor that could be significant in some inflammation and immune res...

CAS 1103672-43-0 S 32826

S 32826
(CAS: 1103672-43-0)

S 32826 is an autotaxin inhibitor (IC50 = 9 nM) exhibiting similar inhibitory effects at all three autotaxin isoforms (α, β and γ). S 32826 displays no affinity...

CAS 108153-74-8 Secretin (human)

Secretin (human)
(CAS: 108153-74-8)

Secretin (human) is a gastrointestinal peptide hormone that stimulates pancreatic and biliary secretion. Secretin (human) is thought to play a role in the regul...

CAS 23674-86-4 Difluprednate

(CAS: 23674-86-4)

Difluprednate (difluoroprednisolone butyrate acetate, or DFBA) is a synthetic difluorinated prednisolone derivative, it is originally developed for dermatologic...

P21d hydrochloride

P21d hydrochloride is a breast tumor kinase inhibitor with IC50 value of 30 nM. It can restore E-cadherin expression and suppress migration in breast cancer cel...

CAS 114084-78-5 Ibandronic acid

Ibandronic acid
(CAS: 114084-78-5)

Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.

CAS 58-85-5 Biotin

(CAS: 58-85-5)

Biotin, also known as vitamin H or coenzyme R, is a water-soluble B-vitamin (vitamin B7).

CAS 35543-24-9 Buflomedil Hydrochloride

Buflomedil Hydrochloride
(CAS: 35543-24-9)

Buflomedil HCl is a vasodilator used to treat claudication or the symptoms of peripheral arterial disease.

CAS 142557-61-7 A 484954

A 484954
(CAS: 142557-61-7)

A 484954 is a eukaryotic elongation factor-2 (eEF-2) kinase inhibitor (IC50 = 0.28 μM in enzymatic assay). A 484954 reduces eEF-2 phosphorylation with little ef...

CAS 1188-38-1 N-Carbamyl-L-Glutamic acid

N-Carbamyl-L-Glutamic acid
(CAS: 1188-38-1)

N-Carbamyl-L-Glutamic acid is an orphan drug which is applicated for the treatment of hyperammonaemia in patients that has N-acetylglutamate synthase deficiency...


7DW8-5, a novel glycolipid, an analog of α-galactosylceramide (α-GalCer), is an immunostimulate iNKT agonist and a vaccine adjuvant that can harness and amplify...

CAS 1340875-03-7 PRMT3 inhibitor 1

PRMT3 inhibitor 1
(CAS: 1340875-03-7)

PRMT3 inhibitor 1 is an allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3; IC50 value of 1.6 μM for inhibition of full length PRMT3 in a radio...

Chemical Structure

CAS 189060-13-7 Lapaquistat acetate

Quick Inquiry

Verification code

Featured Items